The first ever drug to treat dry age-related macular degeneration (AMD) was approved for use in the US earlier this year. The approval is welcome news to the 5 million people worldwide who suffer from this relentlessly progressive, vision-threatening, endstage form of dry AMD. But there are some important things for patients to know about the new treatment. In this segment of “Ask An Ophthalmologist,” Dr. Rahul Khurana addresses some of those issues. Speak with your ophthalmologist to find out if this new treatment is right for you. The FDA approved a second treatment for dry AMD a couple of weeks ago. Rahul N. Khurana, MD, FASRS is a vitreoretinal surgeon at Northern California Retina Vitreous Associates and clinical associate professor of ophthalmology at University of California at San Francisco. He also serves as the Academy’s Secretary for Online Education. • Watch and react on Genuin

@aaoeye

Brand

16w ago

The first ever drug to treat dry age-related macular degeneration (AMD) was approved for use in the US earlier this year. The approval is welcome news to the 5 million people worldwide who suffer from this relentlessly progressive, vision-threatening, endstage form of dry AMD. But there are some important things for patients to know about the new treatment. In this segment of “Ask An Ophthalmologist,” Dr. Rahul Khurana addresses some of those issues. Speak with your ophthalmologist to find out if this new treatment is right for you. The FDA approved a second treatment for dry AMD a couple of weeks ago. Rahul N. Khurana, MD, FASRS is a vitreoretinal surgeon at Northern California Retina Vitreous Associates and clinical associate professor of ophthalmology at University of California at San Francisco. He also serves as the Academy’s Secretary for Online Education.